Ann: Chairman's Address and CEO update, page-3

A shell with very good IP. Anecdotal, but I had their technology in a torn shoulder labrum, which their mesenchymal stem cells fixed under MRI evidence before and after, and of course function and pain.

I don't believe they offer anymore in Australia (a shame, as the invasive surgery alternative horrible).

I like the 12 month lock-in on merger shares. Some investors may hate it, but RGS' future not untied to MSB. If it gets approved next year this company's IP will be a screaming buy at 20 times the mkt cap. MSB will get a yes or no next year.

Stating the obvious, but only Hematopoietic Stem Cells treatments for blood cancers have been approved by the FDA to date, mainly in the autologous sphere (there was arguably an allogeneic approval this year). If MSB on GvHD, or another company gets the nod on FDA (there are plenty others out there) the flood gates of interest will open.